NCT00510250 - A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

July 31, 2015

Conditions

Cancer of the Cervix

Interventions

DRUG

Sorafenib

200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients

DRUG

Cisplatin

40mg/m2 administered weekly via IV, with Radiation

PROCEDURE

Radiation

Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto